Demographic characteristics of all patients by intensity of the preparative regimen
Characteristic . | Myeloablative . | Nonmyeloablative . | P . |
|---|---|---|---|
| No. of patients | 240 | 95 | |
| Median age, y (range) | 8 (0.2-53) | 50 (18-69) | < .01 |
| Median weight, kg (range) | 30 (4-120) | 78 (50-134) | < .01 |
| CMV-positive recipients, no. (%) | 108 (45) | 47 (49) | .46 |
| HLA match, no. (%) | .02 | ||
| 6 of 6 | 28 (12) | 6 (6) | |
| 5 of 6 | 109 (45) | 29 (31) | |
| 3-4 of 6 | 103 (43) | 60 (63) | |
| No. treated with ATG (%) | 174 (73) | 30 (32) | < .01 |
| No. of UCB recipients (%) | < .01 | ||
| Single unit | 192 (80) | 17 (18) | |
| Double unit | 48 (20) | 78 (82) | |
| Median infused nucleated cell dose, × 107/kg (range) | 4.1 (0.7-28.1) | 3.6 (1.1-6.8) | < .01 |
| Median infused CD34+ cell dose × 105/kg (range) | 4.3 (0.4-96.7) | 4.5 (0.7-18.8) | .57 |
| No. with malignant diagnosis (%) | 157 (65) | 93 (98) | .09 |
| Median time to follow-up, y (range) | 1.5 (0.-9.2) | 1.2 (0.3-3.5) | .02 |
Characteristic . | Myeloablative . | Nonmyeloablative . | P . |
|---|---|---|---|
| No. of patients | 240 | 95 | |
| Median age, y (range) | 8 (0.2-53) | 50 (18-69) | < .01 |
| Median weight, kg (range) | 30 (4-120) | 78 (50-134) | < .01 |
| CMV-positive recipients, no. (%) | 108 (45) | 47 (49) | .46 |
| HLA match, no. (%) | .02 | ||
| 6 of 6 | 28 (12) | 6 (6) | |
| 5 of 6 | 109 (45) | 29 (31) | |
| 3-4 of 6 | 103 (43) | 60 (63) | |
| No. treated with ATG (%) | 174 (73) | 30 (32) | < .01 |
| No. of UCB recipients (%) | < .01 | ||
| Single unit | 192 (80) | 17 (18) | |
| Double unit | 48 (20) | 78 (82) | |
| Median infused nucleated cell dose, × 107/kg (range) | 4.1 (0.7-28.1) | 3.6 (1.1-6.8) | < .01 |
| Median infused CD34+ cell dose × 105/kg (range) | 4.3 (0.4-96.7) | 4.5 (0.7-18.8) | .57 |
| No. with malignant diagnosis (%) | 157 (65) | 93 (98) | .09 |
| Median time to follow-up, y (range) | 1.5 (0.-9.2) | 1.2 (0.3-3.5) | .02 |
CMV indicates cytomegalovirus; HLA, human major histocompatibility complex; ATG, antithymocyte globulin; and UCB, umbilical cord blood